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Introduction
Benzidine (BZ) has been known for a long time as a
carcinogen for bladder cancer.  Recent studies also report-
ed that the incidence of bladder cancer is higher in work-
ers exposed to BZ compared to those who were not
exposed1–6).  The Ministry of Labor in Korea and
American Conference of Governmental Industrial
Hygienists (ACGIH) has confirmed BZ as an A1 human
carcinogen with no occupational exposure limit7, 8).  Azo
dyes used widely as a raw material in the production of
fabric, food and cosmetics and are produced in the world
at 700,000 ton a year9).  There are about 200 different
benzidine based azo dyes, which are used in many prod-
ucts including color paper, fabric, leather, rubber, plastic,
and fur10).  BZ is a chemical substance absorbed through
the skin11) as Direct Blue 6 and Direct Black 38.  A study
confirmed that BZ and its metabolites were excreted
through urine12).  
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Abstract:  The objective of this study was to evaluate the effects of pretreatment of ethanol
(EtOH) and phenobarbital (PB), which are known to affect the metabolism of xenobiotics, in the
formation of hemoglobin adducts in rats administered with benzidine (BZ) and Direct Black 38
(DB38).  The experimental rats were divided into BZ and DB38 groups; each group was subdi-
vided into control, EtOH, and PB groups.  Blood samples were separated into hemoglobin and
plasma immediately after obtaining and basic hydrolysis was done to convert the adducts into
aromatic amines.  Hydrolyzed BZ, monoacetylbenzidine (MABZ), and 4-aminobiphenyl (4ABP)
were separated by reversed-phase liquid chromatography without derivatization.  Then, quanti-
tative analyses were performed using a high performance liquid chromatograph equipped with
an electrochemical detector.  The amount of metabolites was expressed in the hemoglobin bind-
ing index (HBI).  As a result, the formations of hemoglobin in BZ-, MABZ-, and 4ABP-HBI
of BZ-EtOH and BZ-PB groups were increased compared with those of BZ-control group.  In
DB38 group, all of HBIs except for BZ-HBI were increased more than those of DB38-control
group regardless of the pretreatment.  These results are attributable to the fact that EtOH and
PB induced N-hydroxylation is related to the formation of hemoglobin adducts.  They indicate
that EtOH not only increases the adduct formation by inducing N-hydroxylation but also induces
N-acetylation.  PB induced N-hydroxylation and increased the adduct formation in BZ group,
but decreased the adduct formation in DB38 group due to decreasing azo reduction.  These results
suggest that the effects of EtOH or PB should be considered in biochemical monitoring of BZ and
DB38 for the assessment of intermittent exposure to BZ and DB38.
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Biochemical assessment on exposure to organic com-
pounds generally includes analyses on urine metabolites,
DNA adducts, and hemoglobin adducts13).  The analysis
on hemoglobin adducts is very effective since it not only
shows the amount absorbed into the body but also can
evaluate individual metabolism characteristics14).
Furthermore, many studies reported that hemoglobin
adducts are useful in the evaluation of exposure15–17).  The
Figure 1 shows that the formation process of adduct of
aromatic amine through combination with hemoglobin in
the body and degradation process of aromatic amine and
hemoglobin by hydrolysis in vitro.
Assessment over exposure is not possible through only
monitoring working environment for carcinogens that
people get exposed to intermittently at low concentrations
and could absorb through the skin such as BZ and DB38.
Hence, it is critical to find the optimal method of assess-
ment for long-term exposure18).  The major metabolites
of BZ include N-hydroxylation and N-acetylation.  These
metabolites are formed simultaneously and thus, counter-
act competitively each other.  N-acetylation plays the role
of detoxification since it lowers the concentration of N-
hydroxyamine, which is a substance that induces genetic
toxicity, through the metabolism of amines19).  Thus, stud-
ies reported that the incidence of bladder cancer is high
when N-acetylation is low20–22).  Benzidine azo dye is
absorbed through the body through a different BZ meta-
bolic process.  After this dye initially dissociates into BZ
after azo reduction, it goes through N-hydroxylation and
N-acetylation.  Ethanol (EtOH) that workers get exposed
to frequently due to their drinking habits would inhibit or
induce oxidation23).  and could increase N-acetylation
when present together with aromatic amine24).  On the
other hand, phenobarbital (PB) was reported to induce
oxidation but inhibit the activity of azo-reductase25).
It is important to evaluate how adduct formation
changes due to substances affecting on N-hydroxylation,
N-acetylation and azo reduction in order to realize bio-
logical monitoring using hemoglobin adducts.  In addi-
tion, the amount of adduct formed by DB38 could be dif-
ferent when it is exposed to BZ at the same molar amount
since DB38, which is the most typical benzidine-based
dye, goes through the BZ metabolism pathway after azo
reduction26).  Although many studies were done on hemo-
globin adducts of BZ and azo dye27–29), there has not been
a study on comparing BZ and azo dye at the same time
or evaluating the effects of exposure to these chemicals
at the same time.  Especially, the simultaneous experi-
ment is necessary to assess the effect degree of ethanol
and phenobarbital on azo reduction of DB38 if consider-
ing that airborne exposure of BZ and DB occurred at the
same time in case of manufacturing or treating the dye.
The purpose of the present study was to evaluate the
effects of hemoglobin adduct formation and N-acetylation
with time and effects of DB38 on azo reduction in order
to assess the effects of EtOH and PB as positive control
on hemoglobin adducts formed with the administration of
BZ and DB38 in rats.
Materials and Methods
Experimental groups and doses
The experimental rats were divided into the benzidine
group (BZ group) and Direct Black 38 group (DB38
group).  Each of these two groups was further subdivid-
ed into EtOH pretreatment group (EtOH group), PB pre-
treatment group (PB group) and control group with no
pretreatment.  Thus, total 6 groups were investigated and
each group included 50 male Sprague-Dawley rats
between 7 to 8 wk old weighing 230 ± 10 g.  The pre-
treatment dose of EtOH was 1 g/kg body weight, which
was 1/10 of the oral LD50 of 10.81 g/kg body weight in
rats30).  The pretreatment dose of PB was 80 mg/kg body
weight.  EtOH and PB diluted in distilled water at
10 ml/kg body weight were orally administered once 24 h
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Fig. 1. Reaction which take place in erythrocytes when
exposed to aromatic amine.
before the administration of BZ and DB38.  Only distilled
water was administered to the rats in the control group at
this time.  DB38 was administered orally by dissolving
in 1,2-propanediol (Sigma, St. Louis, Missouri) by refer-
ring to the one-time oral dose of BZ to compare with the
results of hemoglobin adduct formation due to BZ admin-
istration.  Based on the previous report of Birner et al.27),
oral dose of BZ per one time was administered with
0.5 mmol BZ/kg body weight.  The DB38 was also
administered with same oral dose of BZ in order to objec-
tively compare the difference in adduct formation between
BZ and DB38.  
Blood samples were obtained from the vena cava from
5 rats in each group before the oral administration of BZ
and DB38; and at 30 min, 3 h, 6 h, 9 h, 12 h, 24 h, 48 h,
72 h, 96 h, and 144 h after the administration using
heparin treated syringes.  RBC were separated immedi-
ately after taking blood sample.  
Experimental process
Preparation of blood and hydrolysis of hemoglobin
adducts were done according to the methods suggested by
Sabbioni and Neumann (1990)16).  After recovering BZ,
monoacetylbenzidine (MABZ), and 4-aminobiphenyl
(4ABP), the analysis was done using a reversed-phase
high performance liquid chromatograph (HPLC; Gilson
715 System, GILSON, Villier le Bel, France) equipped
with an electrochemical detector (ICA-5212, TOA
Electronics, Tokyo, Japan).  The column equipped in the
HPLC was HAISIL HL C18 (5 µm, 250 × 4.6 mm) and
its operation temperature was 35˚C.  The mobile phase of
BZ and MABZ was Lithium chloride: Methanol (70 : 30)
and the mobile phase of 4ABP was 0.2% Lithium chlo-
ride: Methanol (50 : 50).  The potential values of elec-
trochemical detector were set to 0.65V for BZ, 0.75V for
MABZ and 0.85V for 4ABP, respectively.  The detection
limit was 1.82 ng/ml in BZ, 1.54 ng/ml in MABZ and
0.2 ng/ml in 4ABP, respectively.
The analysis results were expressed with the hemoglo-
bin binding index (HBI) to compare hemoglobin adducts
of BZ, MABZ, and 4ABP at the same conditions.  HBI
was applied to objectively compare each hemoglobin
adduct formed through administering BZ and DB38 with
same dose under same condition and to assess the effect
of EtOH and PB on azo reduction as a function of time.
The HBI was the value obtained by dividing the number
of mmol of BZ, MABZ, and 4ABP bind to 1 mol of
hemoglobin by the amount of BZ or DB38 administered
and its simplified formula is as follows.  
HBI (hemoglobin adduct/amount administered)
= (mmol cleavage product/mol hemoglobin)
/ (mmol benzidine or Direct Black 38/kg body weight)
We assessed the ratio of N-acetylation with time in
order to determine how N-acetylation of hemoglobin
adducts changes due to EtOH and PB.  The ratio of N-
acetylation was obtained by dividing MABZ-HBI by BZ-
HBI29).  We assessed the HBI ratio of DB38 group by
HBI of BZ group with time in order to determine the rel-
ative effects of EtOH and PB on azo reduction when
DB38 and BZ were administered at the same oral dose
(0.5 mmol/kg).  Kruskal-Wallis test was performed to
determine whether a difference was present in the amount
of BZ, MABZ, and 4ABP bind to hemoglobin in EtOH
group, PB group and control group with time.  We used
Tukey test, which is the multiple comparison method of
ANOVA, after converting the resulting values in the order
to determine the difference with each group.
Results
Effects of ethanol and phenobarbital on hemohglobin
adducts
Effects of ethanol and phenobarbital in BZ group 
No hemoglobin adduct was detected in the samples
obtained before the administration of BZ.  Table 1 shows
BZ-HBI, MABZ-HBI, and 4ABP-HBI with time in BZ-
control group, BZ-EtOH group, and BZ-PB group.  Other
than at 0.5 h, BZ-HBI was higher until 6 h in BZ-con-
trol group compared with in BZ-EtOH group and BZ-PB
group.  It was significantly higher in BZ-control group at
3 h, and in BZ-control group and BZ-EtOH group at 6 h
(p<0.05).  However, after 9 h, the average BZ-HBI was
higher in BZ-EtOH group and BZ-PB group compared
with BZ-control group.  Significantly high BZ-HBI val-
ues were seen at 12 h and 144 h in BZ-EtOH group; and
at 12 h, 48 h, 72 h, 96 h, and 144 h in BZ-PB (p<0.05).
Other than at 0.5 h, MABZ-HBI was higher in BZ-con-
trol group until 6 h and was significantly high at 3 h
(p<0.01).  However, higher average MABZ-HBI values
were seen after 9 h in BZ-EtOH group and BZ-PB group
compared with BZ-control group.  These values were sig-
nificantly high in BZ-EtOH group at 48 h and in BZ-PB
group at 72 h (p<0.05).  4ABP-HBI could not be obtained
at 0.5 h in all groups.  The average 4ABP-HBI value was
higher after 9 h in BZ-EtOH group and BZ-PB group
compared with BZ-control group.  Compared with other
groups, this value was significantly high in BZ-EtOH
group at 12 h, 24 h, 72 h, 96 h, and 144 h; and in BZ-
PB group at 3 h, 6 h, 9 h, 12 h, and 24 h (p<0.05).  
Effects of ethanol and phenobarbital in the Direct Black
38 administered group
No hemoglobin adduct was detected in blood samples
obtained before the administration of DB38.  Table 2
shows BZ-HBI, MABZ-HBI, and 4ABP-HBI with time
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in DB38-control group, DB38-EtOH group and DB38-PB
group (Table 2).  BZ-HBI could not be obtained in DB38-
control group and DB38-PB group at 9 h; and in DB38-
EtOH group at 6 h.  This value was high in DB38-con-
trol group only at 12 h.  At all other times, the average
BZ-HBI value was higher in DB38-EtOH group.  Other
than 0.5 h, the MABZ-HBI value was higher at all other
times in DB38-EtOH group and DB38-PB group com-
pared with DB38-control group.  This value was signifi-
cantly high in DB38-EtOH group at 48 h and 96 h; and
in DB38-PB group at 48 h, 72 h, and 96 h (p<0.05).
4ABP-HBI could not be obtained in DB38-control group
until 3 h, in DB38-EtOH group until 0.5 h, and in DB38-
PB group until 6 h.  Other than at 72 h, the average 4ABP-
HBI value was higher in DB38-EtOH group and DB38-
PB group at all times compared with DB38-control group.
This value was significantly high at 3 h, 6 h, 9 h, 12 h,
24 h, 48 h, 96 h, and 144 h in DB38-EtOH group; and
at 24 h, 72 h, and 96 h in DB38-PB group (p<0.01).  
Effects of ethanol and phenobarital on N-acetylation
Changes of N-acetylation in BZ group
Although the ratio of N-acetylation was between 16.92
to 25.02 between 0.5 h to 24 h in BZ-control group, it
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Table 1.   Hemoglobin binding index of cleavage product by ethanol or phenobarbital pretreatment 24 h before benzidine administration in rat 
Time 
(h)
BZ-HBI MABZ-HBI 4ABP-HBI
BZ-control BZ-EtOH BZ-PB BZ-control BZ-EtOH BZ-PB BZ-control BZ-EtOH BZ-PB
0.5 0.04 ± 0.02 0.070 ± 0.01 0.03 ± 0.01* 0.91 ± 0.18 1.21 ± 0.22 1.02 ± 0.22 ND ND ND
3 0.38 ± 0.01 0.14 ± 0.04 0.18 ± 0.02** 7.10 ± 1.72 3.10 ± 0.73 6.39 ± 1.53** 0.23 ± 0.08 0.13 ± 0.70 0.31 ± 0.08*
6 0.43 ± 0.03 0.40 ± 0.02 0.31 ± 0.02** 10.71 ± 4.97 9.09 ± 1.79 10.72 ± 1.70 0.55 ± 0.12 0.47 ± 0.07 0.77 ± 0.13*
9 0.57 ± 0.06 0.61 ± 0.09 0.61 ± 0.26 12.99 ± 5.07 15.33 ± 5.53 13.09 ± 1.29 0.54 ± 0.09 0.91 ± 0.16 1.37 ± 0.18**
12 0.63 ± 0.08 1.02 ± 0.19 1.07 ± 0.31* 15.81 ± 4.02 20.40 ± 4.05 18.75 ± 4.37 0.82 ± 0.17 1.18 ± 0.16 1.53 ± 0.29**
24 1.18 ± 0.49 1.29 ± 0.42 1.63 ± 0.45 20.02 ± 4.59 31.95 ± 9.74 24.70 ± 7.14 0.64 ± 0.11 1.90 ± 0.20 2.36 ± 0.41**
48 0.66 ± 0.09 0.84 ± 0.130 1.62 ± 0.26** 35.77 ± 5.50 50.01 ± 8.33 38.90 ± 5.01* 2.42 ± 0.20 2.78 ± 0.28 4.32 ± 1.24
72 0.58 ± 0.070 0.65 ± 0.02 1.26 ± 0.81** 29.14 ± 7.42 32.69 ± 8.02 46.37 ± 5.01* 1.71 ± 0.19 2.27 ± 0.30 2.39 ± 1.00*
96 0.49 ± 0.04 0.56 ± 0.07 0.91 ± 0.17** 22.22 ± 7.22 30.90 ± 9.89 36.77 ± 9.49 1.13 ± 0.16 1.68 ± 0.170 1.22 ± 0.17**
144 0.24 ± 0.04 0.47 ± 0.03 0.59 ± 0.21** 12.70 ± 3.92 13.88 ± 3.38 15.69 ± 2.29 0.59 ± 0.13 1.56 ± 0.19 1.19 ± 0.17**
BZ: benzidine; MABZ: monoacetylbenzidine; 4ABP: 4-aminobiphenyl; 
HBI: hemoglobin binding index=(mmol cleavage product/mol hemoglobin)/(mmol benzidine/kg body weight); 
BZ-control: no pretreatment, administration of 0.5 mmol benzidine/kg body weight only; 
BZ-EtOH: pretreatment of 1 g EtOH/kg body weight; 
BZ-PB, pretreatment of 80 mg phenobarbital/kg body weight; 
*p<0.05 **p<0.01 by Kruskal-Wallis test; ND: not detected; Mean ± SD (N=5). 
Table 2.   Hemoglobin binding index of cleavage product by ethanol or phenobarbital pretreatment 24 h before Direct Black 38 adminis-
tration in rat 
Time 
(h)
DB38-HBI MABZ-HBI 4ABP-HBI
DB38-control DB38-EtOH DB38-PB DB38-control DB38-EtOH DB38-PB DB38-control DB38-EtOH DB38-PB
0.5 ND ND ND 0.04 ± 0.04 0.04 ± 0.03 0.04 ± 0.04 ND ND ND
3 ND ND ND 0.04 ± 0.04 0.06 ± 0.07 0.06 ± 0.06 ND 0.13 ± 0.15 ND**
6 ND ND ND 0.04 ± 0.05 0.07 ± 0.09 0.05 ± 0.05 0.01 ± 0.01 0.14 ± 0.02 ND**
9 ND 0.01 ± 0.01 ND 0.09 ± 0.12 0.15 ± 0.15 0.10 ± 0.11 0.03 ± 0.02 0.13 ± 0.02 0.01 ± 0.01**
12 0.19 ± 0.13 0.16 ± 0.03 0.11 ± 0.04 0.87 ± 0.35 1.10 ± 0.51 0.90 ± 0.59 2.41 ± 0.47 8.89 ± 1.31 2.767 ± 0.43**
24 0.430 ± 0.34 0.58 ± 0.09 0.12 ± 0.05 1.68 ± 0.15 6.68 ± 4.31 3.31 ± 1.87 2.78 ± 0.21 13.10 ± 1.53 6.27 ± 0.90**
48 0.08 ± 0.05 0.21 ± 0.15 0.10 ± 0.05 0.52 ± 0.28 0.95 ± 0.22 1.00 ± 0.16* 1.98 ± 0.42 11.48 ± 1.46 2.38 ± 0.43**
72 0.05 ± 0.04 0.20 ± 0.15 0.07 ± 0.06 0.49 ± 0.15 0.52 ± 0.21 0.84 ± 0.06* 1.13 ± 0.20 1.55 ± 0.31 1.97 ± 0.39**
96 0.03 ± 0.05 0.10 ± 0.08 0.02 ± 0.01 0.26 ± 0.08 0.56 ± 0.12 0.64 ± 0.13** 0.14 ± 0.03 1.05 ± 0.18 0.84 ± 0.17**
144 0.03 ± 0.04 0.04 ± 0.06 0.01 ± 0.04 0.12 ± 0.11 0.16 ± 0.14 0.14 ± 0.16 0.10 ± 0.06 0.67 ± 0.13 0.01 ± 0.01**
DB38: direct black 38; MABZ: monoacetylbenzidine; 4ABP: 4-aminobiphenyl; 
HBI: hemoglobin binding index=(mmol cleavage product/mol hemoglobin)/(mmol Direct Black 38/kg body weight); 
DB38-control: no pretreatment, administration of 0.5 mmol Direct Black 38/kg body weight only; 
DB38-EtOH: pretreatment of 1 g EtOH/kg body weight; 
DB38-PB, pretreatment of 80 mg phenobarbital/kg body weight; 
*p<0.05 **p<0.01 by Kruskal-Wallis test; ND: not detected; Mean ± SD (N=5). 
increased significantly after 24 h with the highest value
of 54.15 at 48 h.  The ratio of N-acetylation showed no
significant changes in BZ-EtOH group with the value
being between 17.37 to 25.08 between 0.5 to 24 h.
However, it increased significantly after 24 h with the
highest value being 59.41 by 48 h.  This N-acetylation
ratio was higher in BZ-PB group at 0.5 h, 3 h, and 6 h
compared with BZ-control group and BZ-EtOH group.
Contrarily, this ratio was lower in BZ-PB group after 24 h
compared with BZ-control group and BZ-EtOH group
with the highest ratio being 40.28 at 96 h (Fig. 2). 
Changes of N-acetylation in DB group
The highest ratio of N-acetylation was 10.30 at 72 h in
DB38-control group; was 11.56 at 24 h in DB38-EtOH
group; and was 28.03 at 24 h in DB38-PB group (Fig. 3).
Effects of ethanol and phenobarbital on azo reduction of
DB 38 
The cases that any HBI was not detected in DB38 group
and BZ group were not presented in Table 3.  Since the
BZ-HBI ratio and MABZ-HBI ratio in control group,
EtOH group and PB group (HBI in DB38 group/HBI in
BZ group) was lower than 1 at all times, hemoglobin
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Fig. 3. The ratio of N-acetylation (monoacetylbenzidine-hemoglobin binding index/benzidine-hemo-
globin binding index) by ethanol or Phenobarbital pretreatment 24 h before Direct Black 38 admin-
istration in rat.
Fig. 2. The ratio of N-acetylation (monoacetylbenzidine-hemoglobin binding index/benzidine-hemo-
globin binding index) by ethanol or Phenobarbital pretreatment 24 h before benzidine adminis-
tration in rat.
adducts were formed less when DB38 was administered
compared to when BZ was administered regardless of pre-
treatment.  Especially, the MABZ-HBI ratio was rela-
tively lower compared with the BZ-HBI ratio.  However,
the 4ABP-HBI ratio was higher than 1 in DB38-control
group at 12 h and 24 h; in DB38-EtOH group at 3 h,
12 h, 24 h, and 48 h; and in DB38-PB group at 12 h and
24 h, indicating that formation of hemoglobin adducts in
DB38 group was more than in BZ-control, BZ-EtOH and
BZ-PB groups (Table 3).
Discussion
Biological monitoring using hemoglobin adducts is
being used in ethylene31, 32), propylene oxide33), acry-
lamide34), vinyl chloride35), and benzo(a)pyrene36, 37).
Active studies are being conducted on hemoglobin
adducts of nitrosoamine and 4-aminobiphenyl which are
related with smoking38, 39).  Aromatic amines oxidize into
arylhydroxyamine through N-oxidation when absorbed
into the body.  Arylhydroxyamine is converted to
nitrosoaren due to oxidation reaction.  Nitrosoaren then
produces sulfinic acid amide by binding with -SH group
of glutathione or -SH group of hemoglobin cysteine29).
DB38 shows color due to azo bonding(-N=N-) and is
synthesized through coupling with azo compounds.  The
resulting dye is non-volatile and very stable at room40).
However, when the diazo linkage of dye is broken by an
enzyme41) or heat42), it converts to an aromatic amine.
Dye goes through BZ metabolic process by azo reduction
within the body with studies detecting BZ, MABZ and
DABZ in urine of DB38 exposed workers43–45).  We also
confirmed BZ and its metabolites binding with hemoglo-
bin after oral administration of DB38 in rats in the pre-
sent study.  There has not been a study on comparing BZ
and azo dye at the same time or evaluating the effects of
exposure to these chemicals at the same time.  
Aromatic amines go through N-hydroxylation in order
to bind with hemoglobin.  N-hydroxylation is the process
in which OH-group is added to amine group46) and CYP-
450 plays a major role during this process47–51).  CYP
1A1 and 1A2 are the enzymes that are involved in N-
hydroxylation of BZ.  These enzymes are inhibited by α-
naphthoflavone, ellipticine50), furafylline52, 53), and 6-
methyl-1,3,8-trichlorodibenzofuran54) and induced by β-
naphthoflavone55, 56), 2,3,7,8-tetrachlorodibenzo-p-diox-
ine54), and triethylphosphorothioate57).
Other than at 3 h and 6 h, the average BZ-HBI was
higher in BZ-EtOH group and BZ-PB group compared
with BZ-control group.  Furthermore, MABZ-HBI was
high at all times except at 3 h and 4ABP-HBI was high
at all times.  We believe that these results were due to
EtOH23, 58).  and PB25) inducing CYP-450, which partic-
ipates in N-hydroxylation, increasing hemoglobin adducts
formed at the time of BZ administration.  The average
BZ-HBI formed due to the administration of DB38 was
relatively high at all times after 9 h except at 12 h in
DB38-control group and at 12 h in DB38-EtOH group.
However, unlike BZ-PB group, the average BZ-HBI was
lower at 12 h, 24 h, and 144 h in DB38-PB group com-
pared with DB38-control group due maybe to PB not only
activating N-hydroxylation but also inhibiting azo reduc-
tion59), which is the initial metabolism process of DB38.
Other than at 0.5 h, the average MABZ-HBI in DB38-
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Table 3.   The ratio of Direct Black 38 group’s HBI to benzidine group’s HBI by ethanol or phenobarbital
pretreatment 24 h before benzidine or Direct Black 38 administration in rat 
Time 
(h)
Control EtOH PB
BZ MABZ 4ABP BZ MABZ 4ABP BZ MABZ 4ABP
0.5 - 0.0471 - - 0.0295 - - 0.0375 -
3 - 0.0050 - - 0.0184 1.0026 - 0.0095 -
6 - 0.0033 0.0236 - 0.0078 0.2979 - 0.0049 -
9 - 0.0072 0.0597 0.0058 0.0097 0.1457 - 0.0076 0.0005
12 0.3035 0.0548 2.9604 0.1567 0.0540 7.5592 0.1058 0.0480 1.8118
24 0.3605 0.0841 4.3448 0.4474 0.2091 6.9051 0.0724 0.1340 2.6533
48 0.1271 0.0146 0.8158 0.2453 0.0189 4.1363 0.0632 0.0259 0.5499
72 0.0813 0.0167 0.6619 0.3111 0.0158 0.6830 0.0541 0.0181 0.8210
96 0.0643 0.0118 0.1224 0.1869 0.0183 0.6290 0.0263 0.0173 0.6825
144 0.1218 0.0094 0.1637 0.0865 0.0112 0.4262 0.0088 0.0088 0.0110
HBI: hemoglobin binding index=(mmol cleavage product/mol hemoglobin)/(0.5 mmol benzidine or Direct Black 38/kg
body weight); Control: no pretreatment; EtOH: pretreatment of 1 g EtOH/kg body weight; PB: pretrearment of 80 mg
phenobarbital/kg body weight; BZ: the ratio of Direct Black 38 group’s benzidine-HBI to benzidine group’s benzi-
dine-HBI; MABZ: the ratio of Direct Black 38 group’s monoacetylbenzidine-HBI to benzidine group’s monoacetyl-
benzidine-HBI; 4ABP: the ratio of Direct Black 38 group’s 4-aminobiphenyl-HBI to benzidine group’s 4-amino-
biphenyl-HBI.
EtOH group and DB38-PB group was higher compared
with in DB38-control group.  The average 4ABP-HBI was
also high at all times compared with DB38-control group.
As in the case of BZ group, these results were probably
due to EtOH and PB increasing hemoglobin adducts with
the administration of DB38.
N-acetylation plays the role of increasing solubility by
adding acetate group into nitrogen and oxygen in aromatic
amine or hydroxyamine60).  We relatively evaluated the
ratio of N-acetylation by dividing MABZ-HBI by BZ-HBI
in order to assess N-acetylation occurring in hemoglobin
adducts.  The N-acetylation ratio was the highest in BZ-
control group with 54.15 at 48 h, in BZ-EtOH group with
59.41 at 48 h, and in BZ-PB group with 40.28 at 96 h.
A study reported that N-acetylation increases when
exposed to EtOH together with aromatic amines23, 57).
We could not find any significant difference in the ratio
of N-acetylation although MABZ-HBI in BZ-EtOH group
was actually higher than MABZ-HBI in BZ-control group
due to BZ-HBI in BZ-EtOH group relatively larger than
BZ-HBI in BZ-control group since EtOH increased N-
hydroxylation and N-acetylation about the same
rates23, 24).  BZ-PB group showed a relatively smaller ratio
of N-acetylation after 24 h compared with that in BZ-con-
trol group.  However, we could not simply conclude that
N-acetylation occurred less in BZ-PB group since BZ-
HBI in BZ-PB group was relatively larger than BZ-HBI
in BZ-control group after 24 h.
The N-acetylation ratio in DB38-control group was the
highest at 72 h with 10.30; in DB38-EtOH group at 24 h
with 11.56; and in DB38-PB group at 24 h with 28.03.
When the N-acetylation ratio was compared between BZ
group and DB38 group, it was relatively small in DB38-
control, -EtOH, and -PB groups compared with BZ-con-
trol, -EtOH, and -PB groups.  The ratio of N-acetylation
in DB38-PB group was higher than in DB38-control and
DB38-EtOH groups since azo reduction of DB38 was
inhibited due to PB58) according to relatively smaller BZ-
HBI in DB38-PB group compared with BZ-HBI in DB38-
control and DB3-EtOH group.  The ratio of N-acetylation
was more than 1 in BZ-control, -EtOH, and -PB groups
and in DB38-control, -EtOH and -PB groups at all times,
showing that MABZ-HBI was higher than BZ-HBI.  This
result confirmed that 4-nitroso-4’-N-acetylbiphenyl is
formed the most within RBC when exposed to BZ or
DB38.
Amines with one amine group such as aniline and
4ABP are more useful when acetylation can be explained
in the evaluation of exposure to hemoglobin adducts17)
since the risk for bladder cancer increases when N-
hydroxylation increases competitively due to slowly pro-
gressing N-acetylation61, 62).  However, it is difficult to
explain for toxicity and solubility only with N-acetylation
because deacetylation and N-acetylation occur at the same
time in amines with more than 2 amine groups such as
BZ29).  The rate of N-acetylation progression differs sig-
nificantly according to races.  N-acetylation progresses the
fastest in Asians, followed by Blacks and Caucasians
showing the slowest N-acetylation17).
We determined how much of DB38 was metabolized
by going through BZ by azo reduction within the body
by comparing BZ and HBIs of its metabolites in DB38
and BZ groups.  For this purpose, we assessed the ratio
of HBI in DB38 group divided by HBI in BZ group.  BZ-
HBI ratio and MABZ-HBI ratio in DB38 group were less
than 1 at all times of observation regardless of pretreat-
ment.  Especially, MABZ-HBI ratio was relatively lower
than BZ-HBI ratio, suggesting that DB38 was absorbed
into the body and goes through only part of BZ metabo-
lism process.  When Direct Red 46, which was an azo
dye similar to DB38, was administered in rats, the results
showed that BZ formed hemoglobin adducts at low con-
centrations28), similar to the result shown in the present
study.  However, 4ABP-HBI was higher than 1 in DB38-
control group at 12 h and 24 h; in DB38-EtOH group at
3 h, 12 h, 24 h, and 48 h; and in DB38-PB group at 12 h
and 24 h, with the formation at higher concentrations
compared with BZ group.  These results were similar to
the study done by Birner et al. (1990)27) who used the
BZ azo dye, Direct Black 29.  This cause could not be
explained clearly since the mechanism of 4ABP produc-
tion with BZ metabolites has not been elucidated64), need-
ing further studies in the future.  
When same doses of BZ were administered according
to BZ azo dyes in dogs that have a similar carcinogene-
sis mechanism as humans, the results showed that the
amount of urinary BZ was less BZ administered with the
administration of Direct Black 4 and Direct Red 28 but
was similar with the administration of Direct Green 1 and
Direct Orange 864).  Direct Brown showed more urinary
BZ compared with BZ group65).  Therefore, it is difficult
to apply the study result that hemoglobin adducts pro-
duced through the exposure to DB38 was less than hemo-
globin addcuts produced through the exposure to BZ in
all BZ dyes.
The concentration of hemoglobin adducts was very low
24 h after the azo dye Direct Red 46 and the azo pigment
Yellow 17 were administered in Wistar rats, with espe-
cially low concentration in the less carcinogenic Yellow
17 pigment28).  When hemoglobin adducts were measured
24 h after the oral administration of BZ and 3,3´-
dichlorobenzidine at 0.2 mmol each in Wistar rats, the
results showed that hemoglobin adducts formed very lit-
tle with the administration of less carcinogenic 3,3´-
dichlorobenzidine compared with BZ29), indirectly
explaining the toxicologic significance of hemoglobin
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adducts.  
Because BZ and DB38 were orally administered, a limit
of this study was that a difference could be present in the
absorption and adduct formation in workers at actual work
sites who absorb these chemicals through the respiratory
system and skin.  Furthermore, N-acetylation occurs faster
in the experimental animal Sprague-Dawley rats com-
pared with other rats66).  and adduct formation is differ-
ent according to the type of experimental animals67).
Therefore, MABZ-HBI could have been higher in our
study compared with other studies.  Although BZ causes
bladder cancer in humans6), it causes liver cancer in mice
and rats68).  However, the results more applicable to
humans could be obtained when studies are to be con-
ducted in dogs since BZ causes bladder cancer in dogs
who have similar levels of N-acetylation as in people69).
Conclusion
The formations of hemoglobin in BZ-, MABZ-, and
4ABP-HBI of BZ-EtOH and BZ-PB groups were
increased compared with those of BZ-control group.  In
DB38 group, all of HBIs except for BZ-HBI were
increased more than those of DB38-control group regard-
less of the pretreatment.  These results are attributable to
the fact that EtOH and PB induced N-hydroxylation is
related to the formation of hemoglobin adducts.  They
indicate that EtOH not only increases the adduct forma-
tion by inducing N-hydroxylation but also induces N-
acetylation.  PB induced N-hydroxylation and increased
the adduct formation in BZ group, but decreased the
adduct formation in DB38 group due to decreasing azo
reduction.  These results suggest that the effects of EtOH
or PB should be considered in biochemical monitoring of
BZ and DB38 for the assessment of intermittent exposure
to BZ and DB38.
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